Loading...
XTAI
1789
Market cap458mUSD
Jul 28, Last price  
17.15TWD
1D
0.00%
1Q
-7.82%
Jan 2017
-53.98%
IPO
-64.08%
Name

ScinoPharm Taiwan Ltd

Chart & Performance

D1W1MN
P/E
39.96
P/S
3.98
EPS
0.43
Div Yield, %
1.75%
Shrs. gr., 5y
2.67%
Rev. gr., 5y
3.32%
Revenues
3.41b
+6.91%
3,813,072,0003,891,113,0003,953,578,0004,572,509,0005,088,245,0004,097,844,0003,955,207,0004,030,921,0003,516,481,0003,524,263,0002,892,783,0003,082,928,0002,762,335,0003,264,045,0003,186,083,0003,406,284,000
Net income
339m
+18.22%
1,041,033,0001,040,003,000959,355,0001,170,469,0001,273,404,000484,143,000634,965,000658,693,000422,367,000442,978,000216,656,000282,067,000243,471,000353,216,000287,056,000339,350,000
CFO
751m
+224.89%
1,297,804,0001,564,380,0001,294,307,0001,021,055,000939,473,000888,295,0001,044,530,0001,665,024,000971,714,0001,231,594,000788,945,000946,312,000509,823,000773,791,000231,126,000750,913,000
Dividend
Jul 04, 20240.3 TWD/sh
Earnings
Aug 04, 2025

Profile

ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells cGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. The company offers custom synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; and outsourcing services. It also provides CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates. In addition, the company develops peptide synthesis technologies. Further, it develops and manufactures western medicines and other chemical materials, albumin medicines, oligonucleotide medicines, injections, and new small molecule drugs, as well as provides biological technology services and technical services. It has a strategic alliance with Baxter International Inc. to develop, manufacture, and commercialize of antiemetic drug in chemotherapy for cancer. ScinoPharm Taiwan, Ltd. was incorporated in 1997 and is headquartered in Tainan City, Taiwan.
URL
https://www.scinopharm.com.tw/
IPO date
Oct 29, 2010
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,406,284
6.91%
3,186,083
-2.39%
3,264,045
18.16%
Cost of revenue
3,083,575
2,871,659
2,858,412
Unusual Expense (Income)
NOPBT
322,709
314,424
405,633
NOPBT Margin
9.47%
9.87%
12.43%
Operating Taxes
73,667
61,784
84,744
Tax Rate
22.83%
19.65%
20.89%
NOPAT
249,042
252,640
320,889
Net income
339,350
18.22%
287,056
-18.73%
353,216
45.08%
Dividends
(237,222)
(284,666)
(379,555)
Dividend yield
1.19%
1.36%
1.88%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
56,412
50,872
96,727
Long-term debt
1,260,322
1,158,018
1,180,255
Deferred revenue
Other long-term liabilities
27,606
55,811
76,848
Net debt
(2,849,253)
(2,833,547)
(3,161,283)
Cash flow
Cash from operating activities
750,913
231,126
773,791
CAPEX
(280,169)
(268,429)
(250,044)
Cash from investing activities
(293,383)
(233,290)
(253,618)
Cash from financing activities
(244,887)
(340,977)
(314,827)
FCF
322,682
579,273
(218,915)
Balance
Cash
4,165,987
3,949,828
4,345,841
Long term investments
92,609
92,424
Excess cash
3,995,673
3,883,133
4,275,063
Stockholders' equity
8,387,619
9,099,094
9,155,364
Invested Capital
7,234,491
7,158,211
6,830,110
ROIC
3.46%
3.61%
4.67%
ROCE
2.87%
2.85%
3.65%
EV
Common stock shares outstanding
903,433
792,328
792,681
Price
22.05
-16.48%
26.40
3.73%
25.45
3.25%
Market cap
19,920,705
-4.77%
20,917,459
3.69%
20,173,731
3.30%
EV
17,071,452
18,083,912
17,012,448
EBITDA
810,990
775,591
845,098
EV/EBITDA
21.05
23.32
20.13
Interest
8,083
9,147
7,913
Interest/NOPBT
2.50%
2.91%
1.95%